Pembrolizumab,
does it really help with Prevention of recurrence and distant metastasis in completely resected high-risk stage III melanoma?
research showsAdjuvant pembrolizumab is rated B because it reduces recurrence and distant metastasis after complete resection of high-risk stage III melanoma. KEYNOTE-054 double-blindly randomized 1,019 patients to pembrolizumab or placebo and initially found a recurrence-free-survival hazard ratio of 0.57. At seven years, benefits persisted for recurrence-free survival, HR 0.63, and distant-metastasis-free survival, HR 0.64. Overall survival had not been established at the verification point, so strong direct prevention evidence supports B with 78 points.
ads claimAdjuvant immunotherapy should not be presented as zero recurrence or guaranteed cure. It lowers average recurrence risk, but recurrence still occurs and immune-mediated adverse events are possible.
Useful facts when choosing a product
- Pembrolizumab is a prescription intravenous PD-1-blocking immunotherapy used as adjuvant treatment after complete resection of melanoma at high risk of recurrence.
- Thyroid, liver, and kidney function and symptoms are monitored; new diarrhea, cough, breathlessness, jaundice, or severe fatigue can signal immune-mediated inflammation.
- Immune-mediated pneumonitis, colitis, hepatitis, nephritis, endocrinopathies, and severe skin reactions can occur, including after treatment has ended.
- Immune toxicity may require treatment interruption, discontinuation, or corticosteroids, so new symptoms should be reported promptly to the oncology team.
What the research actually shows
KEYNOTE-054 was a double-blind phase 3 trial randomizing 1,019 patients with completely resected high-risk AJCC-7 stage IIIA, IIIB, or IIIC melanoma to pembrolizumab 200 mg every three weeks for up to 18 doses or placebo. The 2018 primary recurrence-free-survival hazard ratio was 0.57. At 3.5 years, distant-metastasis-free survival was 65.3% versus 49.4%, HR 0.60. In 2024, seven-year recurrence-free survival was 50% versus 36%, HR 0.63, and distant-metastasis-free survival was 54% versus 42%, HR 0.64. The B grade follows the clinical endpoints rather than approval status because overall survival is not established.
Why this is classified as B (78)
A 1,019-participant double-blind placebo-controlled phase 3 trial improved recurrence-free and distant-metastasis-free survival with benefits sustained for seven years. Overall survival remains unestablished and the claim is recurrence prevention, supporting high B with 78 points. Immune toxicity is kept separate under safety.
Counterpoint. Absolute benefit and treatment burden vary with surgical stage, nodal tumor burden, BRAF status, comorbidity, and patient preference.
Rejudgment record. New verdict — The double-blind placebo-controlled KEYNOTE-054 trial demonstrated seven-year durable gains in recurrence-free and distant-metastasis-free survival, but overall survival remains immature, supporting direct recurrence-progression prevention grade B
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Prolonged recurrence-free survival after complete resection of stage III melanoma | B | The placebo-controlled benefit persisted for seven years, but the endpoint is recurrence prevention. |
| Prevention of distant metastasis | B | Seven-year distant-metastasis-free survival was 54% versus 42%, with HR 0.64. |
| Prolonged overall survival | C | An overall-survival benefit was not established at verification, so efficacy is not asserted. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Eggermont AMM et al. 2018 KEYNOTE-054 | Multicenter double-blind randomized placebo-controlled phase 3 trial | 1,019 | Merck Sharp & Dohme | Recurrence-free survival | Pembrolizumab reduced recurrence or death versus placebo, with HR 0.57. | Pivotal molecule-specific placebo-controlled phase 3 evidence |
| Eggermont AMM et al. 2024 KEYNOTE-054 seven-year analysis | Long-term follow-up of the original randomized trial | 1,019 | Merck Sharp & Dohme | Seven-year recurrence-free and distant-metastasis-free survival | Benefits persisted with seven-year recurrence-free-survival HR 0.63 and distant-metastasis-free-survival HR 0.64. | Long-term durability confirmation |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-23).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none
Cite this verdict
[Chamgap] Pembrolizumab x prevention of recurrence and distant metastasis after complete resection of stage III melanoma — Evidence Grade B·78. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/pembrolizumab-resected-stage-three-melanoma-recurrence-prevention/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.